Antibody-Drug Conjugate
JPM 2024: Biotech Companies Mapping Out Their Future, and a New Round of M&A Spree Begins
2024-01-09
Reviewing the Market Trends in the Antibody-Drug Conjugate Development: A Focus on Roche, Sanofi, BMS, Seagen, and BioNTech
2024-01-05
SystImmune Partners with Bristol-Myers Squibb to Develop and Commercialize Bispecific ADC Globally
2023-12-13
2023 ASCO Annual Meeting: Progress in Solid Tumor Treatment Research, and Promising Results in Emerging Therapies
2023-07-03
Following Amgen, Hummingbird Jumps Onto Synaffix’s ADC Platform In $150 Million Licensing Deal
2023-01-06
FDA Grants AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Its Fifth Breakthrough Label
2022-04-28
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115